BRAUNWALD
ET AL., MANAGEMENT OF PATIENTS WITH UNSTABLE ANGINA AND NON-ST-SEGMENT
ELEVATION MYOCARDIAL INFARCTION UPDATE
http://www.acc.org/clinical/guidelines/unstable/incorporated/index.htm
ACC/AHA
2002 Guideline Update for the Management of Patients With
Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction
A
Report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Committee on
the Management of Patients With Unstable Angina)
References
1.
Braunwald E, Mark DB, Jones RH, et al. Unstable angina: diagnosis
and management. Rockville, MD: Agency for Health Care Policy
and Research and the National Heart, Lung, and Blood Institute,
US Public Health Service, US Department of Health and Human
Services; 1994:1. AHCPR Publication 94-0602.
2.
National Center for Health Statistics. Detailed diagnoses
and procedures: National Hospital Discharge Survey, 1996.
Hyattsville, MD: National Center for Health Statistics; 1998:13.
Data from Vital and Health Statistics.
3.
Nourjah P. National Hospital Ambulatory Medical Care Survey:
1997 emergency department summary. Hyattsville, MD: National
Center for Health Statistics; 1999:304. Advance data from
Vital and Health Statistics.
4.
Anderson HV, Cannon CP, Stone PH, et al. One-year results
of the Thrombolysis In Myocardial Infarction (TIMI) IIIB clinical
trial: a randomized comparison of tissue-type plasminogen
activator versus placebo and early invasive versus early conservative
strategies in unstable angina and non-Q wave myocardial infarction.
J Am Coll Cardiol 1995;26:1643-50.
5.
Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines
for the management of patients with acute myocardial infarction:
a report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Committee on
Management of Acute Myocardial Infarction). 1999 update. Available
at: http://www.acc.org/clinical/guidelines/ami.html. Accessed
August 30, 1999.
6.
Wu AH, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes RJ.
National Academy of Clinical Biochemistry Standards of Laboratory
Practice recommendations for the use of cardiac markers in
coronary artery diseases. Clin Chem 1999;45:1104-21.
7.
Braunwald E. Unstable angina: an etiologic approach to management
(editorial). Circulation 1998;98:2219-22.
8.
Braunwald E. Unstable angina classification. Circulation 1989;80:410-4.
9.
Campeau L. Grading of angina pectoris (letter). Circulation
1976;54:522-3.
10.
PURSUIT Trial Investigators. Inhibition of platelet glycoprotein
IIb/IIIa with eptifibatide in patients with acute coronary
syndromes. The PURSUIT Trial InvestigatorsPlatelet Glycoprotein
IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin
Therapy. N Engl J Med 1998;339:436-43.
11.
Selker HP, Beshansky JR, Griffith JL, et al. Use of the acute
cardiac ischemia time-insensitive predictive instrument (ACI-TIPI)
to assist with triage of patients with chest pain or other
symptoms suggestive of acute cardiac ischemia: a multicenter,
controlled clinical trial. Ann Intern Med 1998;129:845-55.
12.
Ghali JK, Cooper RS, Kowatly I, Liao Y. Delay between onset
of chest pain and arrival to the coronary care unit among
minority and disadvantaged patients. J Natl Med Assoc 1993;85:180-4.
13.
Hargarten K, Chapman PD, Stueven HA, et al. Prehospital prophylactic
lidocaine does not favorably affect outcome in patients with
chest pain. Ann Emerg Med 1990;19:1274-79.
14.
Newby LK, Califf RM, Guerci A, et al. Early discharge in the
thrombolytic era: an analysis of criteria for uncomplicated
infarction from the Global Utilization of Streptokinase and
t-PA for Occluded Coronary Arteries (GUSTO) trial. J Am Coll
Cardiol 1996;27:625-32.
15.
Maynard C, Weaver WD, Lambrew C, Bowlby LJ, Rogers WJ, Rubison
RM, for participants in the National Registry of Myocardial
Infarction. Factors influencing the time to administration
of thrombolytic therapy with recombinant tissue plasminogen
activator (data from the National Registry of Myocardial Infarction).
Am J Cardiol 1995;76:548-52.
16.
Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated
vs hospital-initiated thrombolytic therapy: the Myocardial
Infarction Triage and Intervention Trial. JAMA 1993;270:1211-6.
17.
Pope JH, Ruthazer R, Beshansky JR, Griffith JL, Selker HP.
Clinical features of emergency department patients presenting
with symptoms suggestive of acute cardiac ischemiaa multicenter
study. J Thromb Thrombolysis 1998;6:63-74.
18.
Theroux P, Fuster V. Acute coronary syndromes: unstable angina
and non-Q-wave myocardial infarction. Circulation 1998;97:
1195-206.
19.
Effects of tissue plasminogen activator and a comparison of
early invasive and conservative strategies in unstable angina
and non-Q-wave myocardial infarction: results of the TIMI
IIIB trial. Thrombolysis In Myocardial Ischemia. Circulation
1994;89: 1545-56.
20.
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive
drug treatment in older persons with isolated systolic hypertension:
final results of the Systolic Hypertension in the Elderly
Program (SHEP). JAMA 1991;265:3255-64.
21.
Platelet Receptor Inhibition in Ischemic Syndrome Management
in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS)
Study Investigators. Inhibition of the platelet glycoprotein
IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave
myocardial infarction [erratum appears in N Engl J Med 1998;339:415].
N Engl J Med 1998;338:1488-97.
22.
Cohen M, Stinnett S, Weatherley B, et al. Predictors of recurrent
ischemic events and death in unstable coronary artery disease
after treatment with combination antithrombotic therapy. Am
Heart J 2000;139:962-70.
23.
Chaitman BR, Bourassa MG, Davis K, et al. Angiographic prevalence
of high-risk coronary artery disease in patient subsets (CASS).
Circulation 1981;64:360-7.
24.
Pryor DB, Harrell FEJ, Lee KL, Califf RM, Rosati RA. Estimating
the likelihood of significant coronary artery disease. Am
J Med 1983;75:771-80.
25.
Pryor DB, Shaw L, McCants CB, et al. Value of the history
and physical in identifying patients at increased risk for
coronary artery disease. Ann Intern Med 1993;118:81-90.
26.
Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM
guidelines for the management of patients with chronic stable
angina. J Am Coll Cardiol 1999;33:2092-197.
27.
Lee TH, Cook EF, Weisberg M, Sargent RK, Wilson C, Goldman
L. Acute chest pain in the emergency room: identification
and examination of low-risk patients. Arch Intern Med 1985;145:65-9.
28.
Pozen MW, D'Agostino RB, Selker HP, Sytkowski PA, Hood WBJ.
A predictive instrument to improve coronary-care-unit admission
practices in acute ischemic heart disease: a prospective multicenter
clinical trial. N Engl J Med 1984;310:1273-8.
29.
Selker HP, Griffith JL, D'Agostino RB. A tool for judging
coronary care unit admission appropriateness, valid for both
real-time and retrospective use: a time-insensitive predictive
instrument (TIPI) for acute cardiac ischemiaa multicenter
study [erratum appears in Med Care 1992;30:188]. Med Care
1991;29:610-27.
30.
Brieger DB, Mak KH, White HD, et al. Benefit of early sustained
reperfusion in patients with prior myocardial infarction (the
GUSTO-I trial). Global Utilization of Streptokinase and TPA
for Occluded Arteries. Am J Cardiol 1998;81:282-7.
31.
Hochman JS, Tamis JE, Thompson TD, et al, for the Global Use
of Strategies to Open Occluded Coronary Arteries in Acute
Coronary Syndromes IIb Investigators. Sex, clinical presentation,
and outcome in patients with acute coronary syndromes. N Engl
J Med 1999;341:226-32.
32.
Hochman JS, McCabe CH, Stone PH, et al, for the TIMI Investigators:
Thrombolysis In Myocardial Infarction. Outcome and profile
of women and men presenting with acute coronary syndromes:
a report from TIMI IIIB. J Am Coll Cardiol 1997; 30:141-8.
33.
Scirica BM, Moliterno DJ, Every NR, et al, for the GUARANTEE
Investigators. Differences between men and women in the management
of unstable angina pectoris (the GUARANTEE Registry). Am J
Cardiol 1999;84:1145-50.
34.
Holmes DRJ, White HD, Pieper F, Ellis SG, Califf RM, Topol
EJ. Effect of age on outcome with primary angioplasty versus
thrombolysis. J Am Coll Cardiol 1999;33:412-9.
35.
White HD, Barbash GI, Califf RM, et al. Age and outcome with
contemporary thrombolytic therapy: results from the GUSTO-I
trial. Global Utilization of Streptokinase and TPA for Occluded
coronary arteries trial. Circulation 1996;94:1826-33.
36.
Jayes RLJ, Beshansky JR, D'Agostino RB, Selker HP. Do patients'
coronary risk factor reports predict acute cardiac ischemia
in the emergency department? A multicenter study. J Clin Epidemiol
1992;45:621-6.
37.
Mak KH, Moliterno DJ, Granger CB, et al, for the GUSTO-I Investigators:
Global Utilization of Streptokinase and Tissue Plasminogen
Activator for Occluded Coronary Arteries. Influence of diabetes
mellitus on clinical outcome in the thrombolytic era of acute
myocardial infarction. J Am Coll Cardiol 1997;30:171-9.
38.
Mueller HS, Cohen LS, Braunwald E, et al. Predictors of early
morbidity and mortality after thrombolytic therapy of acute
myocardial infarction: analyses of patient subgroups in the
Thrombolysis In Myocardial Infarction (TIMI) trial, phase
II. Circulation 1992;85:1254-64.
39.
Barbash GI, White HD, Modan M, et al. Significance of smoking
in patients receiving thrombolytic therapy for acute myocardial
infarction: experience gleaned from the International Tissue
Plasminogen Activator/Streptokinase Mortality Trial. Circulation
1993;87:53-8.
40.
Barbash GI, White HD, Modan M, et al, for the Investigators
of the International Tissue Plasminogen Activator/Streptokinase
Mortality Trial. Acute myocardial infarction in the young:
the role of smoking. Eur Heart J 1995;16:313-6.
41.
Katz DA, Griffith JL, Beshansky JR, Selker HP. The use of
empiric clinical data in the evaluation of practice guidelines
for unstable angina. JAMA 1996;276:1568-74.
42.
Califf RM, Mark DB, Harrell FEJ, et al. Importance of clinical
measures of ischemia in the prognosis of patients with documented
coronary artery disease. J Am Coll Cardiol 1988;11:20-6.
43.
Califf RM, Phillips HR, Hindman MC, et al. Prognostic value
of a coronary artery jeopardy score. J Am Coll Cardiol 1985;5:1055-63.
44.
White LD, Lee TH, Cook EF, et al, for the Chest Pain Study
Group. Comparison of the natural history of new onset and
exacerbated chronic ischemic heart disease. J Am Coll Cardiol
1990; 16:304-10.
45.
Hochman JS, Sleeper LA, Godfrey E, et al, for the SHOCK Trial
Study Group. SHould we emergently revascularize Occluded Coronaries
for cardiogenic shocK: an international randomized trial of
emergency PTCA/CABG-trial design. Am Heart J 1999; 137:313-21.
45a.
Holmes DR Jr, Berger BP, Hochman JS, et al. Cardiogenic shock
in patients with acute ischemic syndromes with and without
ST-segment elevation. Circulation 1999;100:2067-73.
46.
Selker HP, Zalenski RJ, Antman EM, et al. An evaluation of
technologies for identifying acute cardiac ischemia in the
emergency department: a report from a National Heart Attack
Alert Program Working Group [erratum appears in Ann Emerg
Med 1997;29:310]. Ann Emerg Med 1997;29:13-87.
47.
Rouan GW, Lee TH, Cook EF, Brand DA, Weisberg MC, Goldman
L. Clinical characteristics and outcome of acute myocardial
infarction in patients with initially normal or nonspecific
electrocardiograms (a report from the Multicenter Chest Pain
Study). Am J Cardiol 1989;64:1087-92.
48.
Zaacks SM, Liebson PR, Calvin JE, Parrillo JE, Klein LW. Unstable
angina and non-Q wave myocardial infarction: does the clinical
diagnosis have therapeutic implications? J Am Coll Cardiol
1999;33:107-18.
49.
Savonitto S, Ardissino D, Granger CB, et al. Prognostic value
of the admission electrocardiogram in acute coronary syndromes.
JAMA 1999;281:707-13.
50.
Lee TH, Cook EF, Weisberg MC, Rouan GW, Brand DA, Goldman
L. Impact of the availability of a prior electrocardiogram
on the triage of the patient with acute chest pain. J Gen
Intern Med 1990;5:381-8.
51.
Fesmire FM, Percy RF, Wears RL. Diagnostic and prognostic
importance of comparing the initial to the previous electrocardiogram
in patients admitted for suspected acute myocardial infarction.
South Med J 1991;84:841-6.
52.
Adams JE, Abendschein DR, Jaffe AS. Biochemical markers of
myocardial injury: is MB creatine kinase the choice for the
1990s? Circulation 1993;88:750-63.
53.
Eisenberg PR, Kenzora JL, Sobel BE, Ludbrook PA, Jaffe AS.
Relation between ST segment shifts during ischemia and thrombin
activity in patients with unstable angina. J Am Coll Cardiol
1991;18:898-903.
54.
Matetzky S, Freimark D, Feinberg MS, et al. Acute myocardial
infarction with isolated ST-segment elevation in posterior
chest leads V7-9: "hidden" ST-segment elevations revealing
acute posterior infarction. J Am Coll Cardiol 1999;34:748-53.
55.
de Zwaan C, Bar FW, Janssen JH, et al. Angiographic and clinical
characteristics of patients with unstable angina showing an
ECG pattern indicating critical narrowing of the proximal
LAD coronary artery. Am Heart J 1989;117:657-65.
56.
Haines DE, Raabe DS, Gundel WD, Wackers FJ. Anatomic and prognostic
significance of new T-wave inversion in unstable angina. Am
J Cardiol 1983;52:14-8.
57.
Renkin J, Wijns W, Ladha Z, Col J. Reversal of segmental hypokinesis
by coronary angioplasty in patients with unstable angina,
persistent T wave inversion, and left anterior descending
coronary artery stenosis: additional evidence for myocardial
stunning in humans. Circulation 1990;82:913-21.
58.
McCarthy BD, Wong JB, Selker HP. Detecting acute cardiac ischemia
in the emergency department: a review of the literature. J
Gen Intern Med 1990;5:365-73.
59.
Slater DK, Hlatky MA, Mark DB, Harrell FEJ, Pryor DB, Califf
RM. Outcome in suspected acute myocardial infarction with
normal or minimally abnormal admission electrocardiographic
findings. Am J Cardiol 1987;60:766-70.
60.
Cannon CP, McCabe CH, Stone PH, et al. The electrocardiogram
predicts one-year outcome of patients with unstable angina
and non-Q wave myocardial infarction: results of the TIMI
III Registry ECG Ancillary Study. Thrombolysis In Myocardial
Ischemia. J Am Coll Cardiol 1997;30:133-40.
61.
Ohman EM, Armstrong PW, Christenson RH, et al, for the GUSTO
IIA Investigators. Cardiac troponin T levels for risk stratification
in acute myocardial ischemia. N Engl J Med 1996;335: 1333-41.
62.
Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific
troponin I levels to predict the risk of mortality in patients
with acute coronary syndromes. N Engl J Med 1996;335:1342-9.
63.
Hyde TA, French JK, Wong CK, Straznicky IT, Whitlock RM, White
HD. Four-year survival of patients with acute coronary syndromes
without ST-segment elevation and prognostic significance of
0.5-mm ST-segment depression. Am J Cardiol 1999;84:379-85.
64.
Lloyd-Jones DM, Camargo CAJ, Lapuerta P, Giugliano RP, O'Donnell
CJ. Electrocardiographic and clinical predictors of acute
myocardial infarction in patients with unstable angina pectoris.
Am J Cardiol 1998;81:1182-6.
65.
Kudenchuk PJ, Maynard C, Cobb LA, et al. Utility of the prehospital
electrocardiogram in diagnosing acute coronary syndromes:
the Myocardial Infarction Triage and Intervention (MITI) Project.
J Am Coll Cardiol 1998;32:17-27.
66.
Langer A, Freeman MR, Armstrong PW. ST segment shift in unstable
anginapathophysiology and association with coronary anatomy
and hospital outcome. J Am Coll Cardiol 1989;13:1495-502.
67.
Langer A, Freeman MR, Armstrong PW. Relation of angiographic
detected intracoronary thrombus and silent myocardial ischemia
in unstable angina pectoris. Am J Cardiol 1990;66:1381-2.
68.
Hedges JR, Young GP, Henkel GF, Gibler WB, Green TR, Swanson
JR. Serial ECGs are less accurate than serial CK-MB results
for emergency department diagnosis of myocardial infarction.
Ann Emerg Med 1992;21:1445-50.
69.
Patel DJ, Holdright DR, Knight CJ, et al. Early continuous
ST segment monitoring in unstable angina: prognostic value
additional to the clinical characteristics and the admission
electrocardiogram. Heart 1996;75:222-8.
70.
Patel DJ, Knight CJ, Holdright DR, et al. Long-term prognosis
in unstable angina: the importance of early risk stratification
using continuous ST segment monitoring. Eur Heart J 1998;19:240-9.
71.
McNutt RA, Selker HP. How did the acute ischemic heart disease
predictive instrument reduce unnecessary coronary care unit
admissions? Med Decis Making 1988;8:90-4.
72.
Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction
rulesapplications and methodological standards. N Engl J Med
1985;313:793-9.
73.
Goldman L, Weinberg M, Weisberg M, et al. A computer-derived
protocol to aid in the diagnosis of emergency room patients
with acute chest pain. N Engl J Med 1982;307:588-96.
74.
Goldman L, Cook EF, Brand DA, et al. A computer protocol to
predict myocardial infarction in emergency department patients
with chest pain. N Engl J Med 1988;318:797-803.
75.
Lee TH, Juarez G, Cook EF, et al. Ruling out acute myocardial
infarction: a prospective multicenter validation of a 12-hour
strategy for patients at low risk. N Engl J Med 1991;324:1239-46.
76.
Grijseels EW, Deckers JW, Hoes AW, et al. Pre-hospital triage
of patients with suspected myocardial infarction: evaluation
of previously developed algorithms and new proposals. Eur
Heart J 1995;16:325-32.
77.
Ellis AK. Serum protein measurements and the diagnosis of
acute myocardial infarction. Circulation 1991;83:1107-9.
78.
Roberts R, Kleiman NS. Earlier diagnosis and treatment of
acute myocardial infarction necessitates the need for a "new
diagnostic mind-set." Circulation 1994;89:872-81.
79.
Roberts R, Fromm RE. Management of acute coronary syndromes
based on risk stratification by biochemical markers: an idea
whose time has come. Circulation 1998;98:1831-3.
80.
Tsung SH. Several conditions causing elevation of serum CK-MB
and CK-BB. Am J Clin Pathol 1981;75:711-5.
81.
Mair J, Morandell D, Genser N, Lechleitner P, Dienstl F, Puschendorf
B. Equivalent early sensitivities of myoglobin, creatine kinase
MB mass, creatine kinase isoform ratios, and cardiac troponins
I and T for acute myocardial infarction. Clin Chem 1995;41:1266-72.
82.
Puleo PR, Meyer D, Wathen C, et al. Use of a rapid assay of
subforms of creatine kinase-MB to diagnose or rule out acute
myocardial infarction. N Engl J Med 1994;331:561-6.
83.
Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz
T. Emergency room triage of patients with acute chest pain
by means of rapid testing for cardiac troponin T or troponin
I. N Engl J Med 1997;337:1648-53.
84.
Antman EM, Grudzien C, Mitchell RN, Sacks DB. Detection of
unsuspected myocardial necrosis by rapid bedside assay for
cardiac troponin T. Am Heart J 1997;133:596-8.
85.
Apple FS, Falahati A, Paulsen PR, Miller EA, Sharkey SW. Improved
detection of minor ischemic myocardial injury with measurement
of serum cardiac troponin I. Clin Chem 1997;43:2047-51.
86.
Pettijohn TL, Doyle T, Spiekerman AM, Watson LE, Riggs MW,
Lawrence ME. Usefulness of positive troponin-T and negative
creatine kinase levels in identifying high-risk patients with
unstable angina pectoris. Am J Cardiol 1997;80:510-1.
87.
Galvani M, Ottani F, Ferrini D, et al. Prognostic influence
of elevated values of cardiac troponin I in patients with
unstable angina. Circulation 1997;95:2053-9.
88.
Lindahl B, Andren B, Ohlsson J, Venge P, Wallentin L. Risk
stratification in unstable coronary artery disease: additive
value of troponin T determinations and pre-discharge exercise
tests. FRISK Study Group. Eur Heart J 1997;18:762-70.
89.
Lindahl B, Venge P, Wallentin L. Relation between troponin
T and the risk of subsequent cardiac events in unstable coronary
artery disease. The FRISC Study Group. Circulation 1996;93:1651-7.
90.
Wu AH. A comparison of cardiac troponin T and cardiac troponin
I in patients with acute coronary syndromes. Coron Artery
Dis 1999;10:69-74.
91.
Hamm CW, Heeschen C, Goldmann B, et al, for the c7E3 Fab Antiplatelet
Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.
Benefit of abciximab in patients with refractory unstable
angina in relation to serum troponin T levels. N Engl J Med
1999;340:1623-9.
92.
Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White
HD, for the PRISM Study Investigators: Platelet Receptor Inhibition
in Ischemic Syndrome Management. Troponin concentrations for
stratification of patients with acute coronary syndromes in
relation to therapeutic efficacy of tirofiban. Lancet 1999;354:1757-62.
93.
Lindahl B, Venge P, Wallentin L, for the Fragmin in Unstable
Coronary Artery Disease (FRISC) Study Group. Troponin T identifies
patients with unstable coronary artery disease who benefit
from long-term antithrombotic protection. J Am Coll Cardiol
1997;29:43-8.
94.
Antman EM, Sacks DB, Rifai N, McCabe CH, Cannon CP, Braunwald
E. Time to positivity of a rapid bedside assay for cardiac-specific
troponin T predicts prognosis in acute coronary syndromes:
a Thrombolysis In Myocardial Infarction (TIMI) 11A substudy.
J Am Coll Cardiol 1998;31:326-30.
95.
Hamm CW, Ravkilde J, Gerhardt W, et al. The prognostic value
of serum troponin T in unstable angina. N Engl J Med 1992;327:146-50.
96.
Christenson RH, Duh SH, Newby LK, et al, for the GUSTO-IIa
Investigators. Cardiac troponin T and cardiac troponin I:
relative values in short-term risk stratification of patients
with acute coronary syndromes. Clin Chem 1998;44:494-501.
97.
Gokhan CV, Gok H, Kaptanoglu B. The prognostic value of serum
troponin T in unstable angina. Int J Cardiol 1996;53:237-44.
98.
Ravkilde J, Nissen H, Horder M, Thygesen K. Independent prognostic
value of serum creatine kinase isoenzyme MB mass, cardiac
troponin T and myosin light chain levels in suspected acute
myocardial infarction: analysis of 28 months of follow-up
in 196 patients. J Am Coll Cardiol 1995;25:574-81.
99.
Ravkilde J, Horder M, Gerhardt W, et al. Diagnostic performance
and prognostic value of serum troponin T in suspected acute
myocardial infarction. Scand J Clin Lab Invest 1993;53:677-85.
100.
Stubbs P, Collinson P, Moseley D, Greenwood T, Noble M. Prospective
study of the role of cardiac troponin T in patients admitted
with unstable angina. BMJ 1996;313:262-4.
101.
Luscher MS, Thygesen K, Ravkilde J, Heickendorff L, for the
TRIM Study Group: Thrombin Inhibition in Myocardial ischemia.
Applicability of cardiac troponin T and I for early risk stratification
in unstable coronary artery disease. Circulation 1997;96:2578-85.
102.
Brscic E, Chiappino I, Bergerone S, et al. Prognostic implications
of detection of troponin I in patients with unstable angina
pectoris. Am J Cardiol 1998;82:971-3.
103.
Olatidoye AG, Wu AH, Feng YJ, Waters D. Prognostic role of
troponin T versus troponin I in unstable angina pectoris for
cardiac events with meta-analysis comparing published studies.
Am J Cardiol 1998;81:1405-10.
104.
Rebuzzi AG, Quaranta G, Liuzzo G, et al. Incremental prognostic
value of serum levels of troponin T and C-reactive protein
on admission in patients with unstable angina pectoris. Am
J Cardiol 1998;82:715-9.
105.
Yang Z, Zhang W, Liu Y. Prognostic efficacy of troponin T
measurement in angina pectoris. Chin Med J (Engl) 1995;108:626-30.
106.
Kontos MC, Anderson FP, Schmidt KA, Ornato JP, Tatum JL, Jesse
RL. Early diagnosis of acute myocardial infarction in patients
without ST-segment elevation. Am J Cardiol 1999;83: 155-8.
107.
Zaninotto M, Altinier S, Lachin M, Celegon L, Plebani M. Strategies
for the early diagnosis of acute myocardial infarction using
biochemical markers. Am J Clin Pathol 1999;111:399-405.
108.
Zimmerman J, Fromm R, Meyer D, et al. Diagnostic Marker Cooperative
Study for the diagnosis of myocardial infarction. Circulation
1999;99:1671-7.
109.
Apple FS. Clinical and analytical standardization issues confronting
cardiac troponin I. Clin Chem 1999;45:18-20.
110.
Kontos MC, Anderson FP, Hanbury CM, Roberts CS, Miller WG,
Jesse RL. Use of the combination of myoglobin and CK-MB mass
for the rapid diagnosis of acute myocardial infarction. Am
J Emerg Med 1997;15:14-9.
111.
Lindahl B, Venge P, Wallentin L, for the BIOMACS Study Group:
Biochemicals Markers of Acute Coronary Syndromes. Early diagnosis
and exclusion of acute myocardial infarction using biochemical
monitoring. Coron Artery Dis 1995;6:321-8.
111a.
Hamm CW, Braunwald E. A classification of unstable angina
revisited. Circulation 2000;102:118-22.
112.
Apple FS, Christenson RH, Valdes RJ, et al. Simultaneous rapid
measurement of whole blood myoglobin, creatine kinase MB,
and cardiac troponin I by the triage cardiac panel for detection
of myocardial infarction. Clin Chem 1999;45:199-205.
113.
Fesmire FM, Percy RF, Bardoner JB, Wharton DR, Calhoun FB.
Serial creatinine kinase (CK) MB testing during the emergency
department evaluation of chest pain: utility of a 2-hour deltaCK-MB
of +1.6 ng/ml. Am Heart J 1998;136:237-44.
114.
Fesmire FM. Delta CK-MB outperforms delta troponin I at 2
hours during the initial EF evaluation of chest pain. Am J
Emerg Med 2000;18:1-8.
115.
Ardissino D, Merlini PA, Gamba G, et al. Thrombin activity
and early outcome in unstable angina pectoris. Circulation
1996;93: 1634-9.
116.
Becker RC, Cannon CP, Bovill EG, et al. Prognostic value of
plasma fibrinogen concentration in patients with unstable
angina and non-Q-wave myocardial infarction (TIMI IIIB trial).
Am J Cardiol 1996;78:142-7.
117.
Morrow DA, Rifai N, Antman EM, et al. Serum amyloid A predicts
early mortality in acute coronary syndromes: a TIMI 11A substudy.
J Am Coll Cardiol 2000;35:358-62.
118.
Oltrona L, Ardissino D, Merlini PA, Spinola A, Chiodo F, Pezzano
A. C-reactive protein elevation and early outcome in patients
with unstable angina pectoris. Am J Cardiol 1997;80:1002-6.
119.
Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated levels of
interleukin-6 in unstable angina. Circulation 1996;94:874-7.
120.
Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB,
for the European Concerted Action on Thrombosis and Disabilities
Angina Pectoris Study Group. Production of C-reactive protein
and risk of coronary events in stable and unstable angina.
Lancet 1997;349:462-6.
121.
Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is
a potent predictor of mortality independently of and in combination
with troponin T in acute coronary syndromes: a TIMI 11A substudy.
Thrombolysis In Myocardial Infarction. J Am Coll Cardiol 1998;31:1460-5.
122.
Ghaisas NK, Shahi CN, Foley B, et al. Elevated levels of circulating
soluble adhesion molecules in peripheral blood of patients
with unstable angina. Am J Cardiol 1997;80:617-9.
123.
Cannon CP, O'Gara PT. Critical pathways for acute coronary
syndromes. In: Cannon CP, ed. Management of acute coronary
syndromes. Humana Press; Totowa, NJ: 1999:611-27.
124.
Graff L, Joseph T, Andelman R, et al. American College of
Emergency Physicians information paper: chest pain units in
emergency departments: a report from the Short-Term Observation
Services Section. Am J Cardiol 1995;76:1036-9.
125.
Brillman J, Mathers-Dunbar L, Graff L, et al. Management of
observation units. Ann Emerg Med 1995;25:823-30.
126.
Graff LG, Dallara J, Ross MA, et al. Impact on the care of
the emergency department chest pain patient from the Chest
Pain Evaluation Registry (CHEPER) study. Am J Cardiol 1997;80:563-8.
127.
Gomez MA, Anderson JL, Karagounis LA, Muhlestein JB, Mooers
FB. An emergency department-based protocol for rapidly ruling
out myocardial ischemia reduces hospital time and expense:
results of a randomized study (ROMIO). J Am Coll Cardiol 1996;28:25-33.
128.
Farkouh ME, Smars PA, Reeder GS, et al, for the Chest Pain
Evaluation in the Emergency Room (CHEER) Investigators. A
clinical trial of a chest-pain observation unit for patients
with unstable angina. N Engl J Med 1998;339:1882-8.
129.
Newby LK, Mark DB. The chest-pain unit-ready for prime time
(editorial)? N Engl J Med 1998;339:1930-2.
130.
Kuntz KM, Fleischmann KE, Hunink MGM, Douglas PS. Cost-effectiveness
of diagnostic strategies for patients with chest pain. Ann
Intern Med 1999;130:709-18.
131.
Garber AM, Solomon NA. Cost-effectiveness of alternative test
strategies for the diagnosis of coronary artery disease. Ann
Intern Med 1999;130:719-28.
132.
Pepine CJ, Allen HD, Bashore TM, et al. ACC/AHA guidelines
for cardiac catheterization and cardiac catheterization laboratories.
American College of Cardiology/American Heart Association
Ad Hoc Task Force on Cardiac Catheterization. J Am Coll Cardiol
1991;18:1149-82.
133.
Armstrong PW. Stable ischemic syndromes. In: Topol EJ, ed..
Textbook of cardiovascular medicine. Philadelphia, PA: Lippincott-Raven;
1998:333-64.
134.
Cheitlin MD, Hutter AMJ, Brindis RG, et al. ACC/AHA expert
consensus documentuse of sildenafil (Viagra) in patients with
cardiovascular disease: American College of Cardiology/American
Heart Association. J Am Coll Cardiol 1999;33:273-82.
135.
Physicians' desk reference, 3rd ed. Mountvale, NJ: Medical
Economic Co, Inc.; 1999:55.
136.
Dellborg M, Gustafsson G, Swedberg K. Buccal versus intravenous
nitroglycerin in unstable angina pectoris. Eur J Clin Pharmacol
1991;41:5-9.
137.
Yusuf S, Collins R, MacMahon S, Peto R. Effect of intravenous
nitrates on mortality in acute myocardial infarction: an overview
of the randomised trials. Lancet 1988;1:1088-92.
138.
ISIS-4 (Fourth International Study of Infarct Survival) Collaborative
Group. ISIS-4: a randomised factorial trial assessing early
oral captopril, oral mononitrate, and intravenous magnesium
sulphate in 58,050 patients with suspected acute myocardial
infarction. Lancet 1995;345:669-85.
139.
GISSI-3: Gruppo Italiano per lo Studio della Sopravvivenza
nell'infarto Miocardico. Effects of lisinopril and transdermal
glyceryl trinitrate singly and together on 6-week mortality
and ventricular function after acute myocardial infarction.
Lancet 1994;343:1115-22.
140.
Figueras J, Lidon R, Cortadellas J. Rebound myocardial ischaemia
following abrupt interruption of intravenous nitroglycerin
infusion in patients with unstable angina at rest. Eur Heart
J 1991;12:405-11.
141.
Armstrong PW. Stable ischemic syndromes: section 2: clinical
cardiology (Califf RM, section ed.) In: Topol EJ. Textbook
of cardiovascular medicine. Philadelphia, PA: Lippincott-Raven;
1998:351-3.
142.
Yusuf S, Wittes J, Friedman L. Overview of results of randomized
clinical trials in heart disease, II: unstable angina, heart
failure, primary prevention with aspirin, and risk factor
modification. JAMA 1988;260:2259-63.
143.
White HD. Unstable angina: ischemic syndromes. In: Topol EJ,
ed. Textbook of cardiovascular medicine. Philadelphia, PA:
Lippincott-Raven; 1998:365-93.
144.
Furberg CD, Psaty BM, Meyer JV. Nifedipinedose-related increase
in mortality in patients with coronary heart disease. Circulation
1995;92:1326-31.
145.
Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction
in patients with non-Q-wave myocardial infarction: results
of a double-blind, randomized, multicenter trial. N Engl J
Med 1986;315:423-9.
146.
Lubsen J, Tijssen JG. Efficacy of nifedipine and metoprolol
in the early treatment of unstable angina in the coronary
care unit: findings from the Holland Interuniversity Nifedipine/metoprolol
Trial (HINT). Am J Cardiol 1987;60:18A-25A.
147.
Hansen JF, Hagerup L, Sigurd B, et al, for the Danish Verapamil
Infarction Trial (DAVIT) Study Group. Cardiac event rates
after acute myocardial infarction in patients treated with
verapamil and trandolapril versus trandolapril alone. Am J
Cardiol 1997;79:738-41.
148.
Opie LH. Pharmacologic options for treatment of ischemic heart
disease. In: Smith TW. Cardiovascular therapeutics: a companion
to Braunwald's heart disease, Philadelphia, PA: WB Saunders;
1996:22-57.
149.
Beevers DG, Sleight P. Short acting dihydropyridine (vasodilating)
calcium channel blockers for hypertension: is there a risk?
BMJ 1996;312:1143-5.
150.
Pepine CJ, Faich G, Makuch R. Verapamil use in patients with
cardiovascular disease: an overview of randomized trials.
Clin Cardiol 1998;21:633-41.
151.
Danish Study Group on Verapamil in Myocardial Infarction.
Verapamil in acute myocardial infarction. Eur Heart J 1984;5:516-28.
152.
Tijssen JG, Lubsen J. Nifedipine and metoprolol in unstable
angina: findings from the Holland Interuniversity Nifedipine/metoprolol
Trial (HINT). J Cardiovasc Pharmacol 1987;10(Suppl 2):S15-24.
153.
Held PH, Yusuf S, Furberg CD. Calcium channel blockers in
acute myocardial infarction and unstable angina: an overview.
BMJ 1989;299:1187-92.
154.
Boden WE, Krone RJ, Kleiger RE, et al, for the Multicenter
Diltiazem Post-Infarction Trial Research Group. Electrocardiographic
subset analysis of diltiazem administration on long-term outcome
after acute myocardial infarction. Am J Cardiol 1991;67:335-42.
155.
Danish Study Group on Verapamil in Myocardial Infarction.
Secondary prevention with verapamil after myocardial infarction.
Am J Cardiol 1990;66:33I-40I.
156.
Hansen JF, Tingsted L, Rasmussen V, Madsen JK, Jespersen CM.
Verapamil and angiotensin-converting enzyme inhibitors in
patients with coronary artery disease and reduced left ventricular
ejection fraction. Am J Cardiol 1996;77:16D-21D.
157.
Theroux P, Gregoire J, Chin C, Pelletier G, de Guise P, Juneau
M. Intravenous diltiazem in acute myocardial infarction: Diltiazem
as Adjunctive Therapy to Activase (DATA) trial. J Am Coll
Cardiol 1998;32:620-8.
158.
Boden WE, Scheldewaert R, Walters EG, et al, for the Incomplete
Infarction Trial of European Research Collaborators Evaluating
Prognosis Post-Thrombolysis (diltiazem) (INTERCEPT) Research
Group. Design of a placebo-controlled clinical trial of long-acting
diltiazem and aspirin versus aspirin alone in patients receiving
thrombolysis with a first acute myocardial infarction. Am
J Cardiol 1995;75:1120-3.
159.
Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on
myocardial infarction and unstable angina in patients with
low ejection fractions. Lancet 1992;340:1173-8.
160.
Rutherford JD, Pfeffer MA, Moye LA, et al. Effects of captopril
on ischemic events after myocardial infarction: results of
the Survival and Ventricular Enlargement trial: SAVE Investigators.
Circulation 1994;90:1731-8.
161.
ACE Inhibitor Myocardial Infarction Collaborative Group. Indications
for ACE inhibitors in the early treatment of acute myocardial
infarction: systematic overview of individual data from 100,000
patients in randomized trials. Circulation 1998;97:2202-12.
161a.
Flather M, Yusuf S, Kober L, et al. Long-term ACE-inhibitor
therapy in patients with heart failure or left ventricular
dysfunction: a systematic overview of data from individual
patients. Lancet 2000;355:1575-81.
162.
Gustafsson I, Torp-Pedersen C, Kober L, Gustafsson F, Hildebrandt
P. Effect of the angiotensin-converting enzyme inhibitor trandolapril
on mortality and morbidity in diabetic patients with left
ventricular dysfunction after acute myocardial infarction.
Trace Study Group. J Am Coll Cardiol 1999;34:83-9.
163.
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G,
for the Heart Outcomes Prevention Evaluation Study Investigators.
Effects of an angiotensin-converting-enzyme inhibitor, ramipril,
on cardiovascular events in high-risk patients. N Engl J Med
2000;342:145-53.
164.
TenVaarwerk IA, Jessurun GA, DeJongste MJ, et al, for the
Working Group on Neurocardiology. Clinical outcome of patients
treated with spinal cord stimulation for therapeutically refractory
angina pectoris. Heart 1999;82:82-8.
165.
Arora RR, Chou TM, Jain D, et al. The multicenter study of
enhanced external counterpulsation (MUST-EECP): effect of
EECP on exercise-induced myocardial ischemia and anginal episodes.
J Am Coll Cardiol 1999;33:1833-40.
166.
Conti CR. EECP-enhanced external counterpulsation. J Am Coll
Cardiol 1999;33:1841-2.
167.
Hautvast RW, DeJongste MJ, Staal MJ, van Gilst WH, Lie KI.
Spinal cord stimulation in chronic intractable angina pectoris:
a randomized, controlled efficacy study. Am Heart J 1998;136:
1114-20.
168.
Patel DJ, Purcell HJ, Fox KM. Cardioprotection by opening
of the K(ATP) channel in unstable angina. Is this a clinical
manifestation of myocardial preconditioning: results of a
randomized study with nicorandil. CESAR 2 investigation. Clinical
European studies in angina and revascularization. Eur Heart
J 1999;20:51-7.
169.
Cohen M, Demers C, Gurfinkel EP, et al, for the Efficacy and
Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events
Study Group. A comparison of low-molecular-weight heparin
with unfractionated heparin for unstable coronary artery disease.
N Engl J Med 1997;337:447-52.
170.
Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents
death and cardiac ischemic events in unstable angina/non-Q-wave
myocardial infarction: results of the Thrombolysis In Myocardial
Infarction (TIMI) 11B trial. Circulation 1999;100:1593-601.
171.
Antman EM, Cohen M, Radley D, et al. Assessment of the treatment
effect of enoxaparin for unstable angina/non-Q-wave myocardial
infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-8.
172.
Cohen M, Theroux P, Weber S, et al. Combination therapy with
tirofiban and enoxaparin in acute coronary syndromes. Int
J Cardiol 1999;71:273-81.
173.
Antiplatelet Trialists' Collaboration. Collaborative overview
of randomised trials of antiplatelet therapy, I: prevention
of death, myocardial infarction, and stroke by prolonged antiplatelet
therapy in various categories of patients [erratum appears
in BMJ 1994;308:1540]. BMJ 1994;308:81-106.
174.
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH.
Inflammation, aspirin, and the risk of cardiovascular disease
in apparently healthy men [erratum appears in N Engl J Med
1997;337:356]. N Engl J Med 1997;336:973-9.
175.
Lewis HDJ, Davis JW, Archibald DG., et al. Protective effects
of aspirin against acute myocardial infarction and death in
men with unstable angina: results of a Veterans Administration
Cooperative Study. N Engl J Med 1983;309:396-403.
176.
Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone,
or both in unstable angina: results of a Canadian multicenter
trial. N Engl J Med 1985;313:1369-75.
177.
Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or
both to treat acute unstable angina. N Engl J Med 1988;319:1105-11.
178.
RISC Group. Risk of myocardial infarction and death during
treatment with low dose aspirin and intravenous heparin in
men with unstable coronary artery disease. Lancet 1990;336:827-30.
179.
Cohen M, Adams PC, Parry G, et al, for the Antithrombotic
Therapy in Acute Coronary Syndromes Research Group. Combination
antithrombotic therapy in unstable rest angina and non-Q-wave
infarction in nonprior aspirin users: primary end points analysis
from the ATACS trial. Circulation 1994;89:81-8.
180.
Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight
heparin versus regular heparin or aspirin in the treatment
of unstable angina and silent ischemia. J Am Coll Cardiol
1995;26:313-8.
181.
Fragmin during Instability in Coronary Artery Disease (FRISC)
Study Group. Low-molecular-weight heparin during instability
in coronary artery disease. Lancet 1996;347:561-8.
182.
Randomised placebo-controlled trial of abciximab before and
during coronary intervention in refractory unstable angina:
the CAPTURE Study [erratum appears in Lancet 19976;350:744].
Lancet 1997;349:1429-35.
183.
PARAGON Investigators: Platelet IIb/IIIa Antagonism for the
Reduction of Acute coronary syndrome events in a Global Organization
Network. International, randomized, controlled trial of lamifiban
(a platelet glycoprotein IIb/IIIa inhibitor), heparin, or
both in unstable angina. Circulation 1998;97:2386-95.
184.
Platelet Receptor Inhibition in Ischemic Syndrome Management
(PRISM) Study Investigators. A comparison of aspirin plus
tirofiban with aspirin plus heparin for unstable angina. N
Engl J Med 1998;338:1498-505.
185.
ISIS-2. ISIS-2 (Second International Study of Infarct Survival)
Collaborative Group. Randomised trial of intravenous streptokinase,
oral aspirin, both, or neither among 17,187 cases of suspected
acute myocardial infarction. Lancet 1988;2:349-60.
186.
Song KH, Fedyk R, Hoover R. Interaction of ACE inhibitors
and aspirin in patients with congestive heart failure. Ann
Pharmacother 1999;33:375-7.
187.
Schror K. The basic pharmacology of ticlopidine and clopidogrel.
Platelets 1993;4:252-61.
188.
Balsano F, Rizzon P, Violi F, et al for the Studio della Ticlopidina
nell'Angina Instabile Group. Antiplatelet treatment with ticlopidine
in unstable angina: a controlled multicenter clinical trial.
Circulation 1990;82:17-26.
189.
Love BB, Biller J, Gent M. Adverse haematological effects
of ticlopidine: prevention, recognition and management. Drug
Safety 1998;19:89-98.
190.
CAPRIE Steering Committee. A randomised, blinded, trial of
Clopidogrel versus Aspirin in Patients at Risk of Ischaemic
Events (CAPRIE). 1996;348:1329-39.
191.
Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic
purpura associated with clopidogrel. N Engl J Med 2000;342:1773-7.
192.
Muller C, Buttner HJ, Petersen J, Roskamm H. A randomized
comparison of clopidogrel and aspirin versus ticlopidine and
aspirin after the placement of coronary-artery stents. Circulation
2000;101:590-3.
193.
The SYMPHONY Investigators: Sibrafiban versus Aspirin to Yield
Maximum Protection from Ischemic Heart Events Post-acute Coronary
Syndromes. Comparison of sibrafiban with aspirin for prevention
of cardiovascular events after acute coronary syndromes: a
randomised trial. Lancet 2000;355:337-45.
193a.
Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein
IIb/IIIa inhibition with orbofiban in patients with unstable
coronary syndromes (OPUS-TIMI 16) Trial. Circulation 2000;102:
149-56.
193b.
O'Neill WW, Serruys P, Knudtson M, et al. Long-term treatment
with a platelet glycoprotein-receptor antagonist after percutaneous
coronary revascularization. N Engl J Med 2000;342:1316-24.
194.
Hirsh J. Heparin. N Engl J Med 1991;324:1565-74.
195.
Weitz JI. Low-molecular-weight heparins [erratum appears in
N Engl J Med 1997;337:1567] N Engl J Med 1997;337:688-98.
196.
Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin
by hirudin. Biochemistry 1986;25:4622-8.
197.
Bittl JA, Strony J, Brinker JA, et al, for the Hirulog Angioplasty
Study Investigators. Treatment with bivalirudin (Hirulog)
as compared with heparin during coronary angioplasty for unstable
or postinfarction angina. N Engl J Med 1995;333:764-9.
198.
Fuchs J, Cannon CP. Hirulog in the treatment of unstable angina:
results of the Thrombin Inhibition in Myocardial Ischemia
(TIMI) 7 trial. Circulation 1995;92:727-33.
199.
Kong DF, Topol EJ, Bittl JA, et al. Clinical outcomes of bivalirudin
for ischemic heart disease. N Engl J Med 1999;100: 2049-53.
200.
Telford AM, Wilson C. Trial of heparin versus atenolol in
prevention of myocardial infarction in intermediate coronary
syndrome. Lancet 1981;1:1225-28.
201.
Williams DO, Kirby MG, McPherson K, Phear DN. Anticoagulant
treatment of unstable angina. Br J Clin Pract 1986; 40:114-6.
202.
Theroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M.
Aspirin versus heparin to prevent myocardial infarction during
the acute phase of unstable angina. Circulation 1993;88:2045-8.
203.
Neri SG, Gensini GF, Poggesi L, et al. Effect of heparin,
aspirin, or alteplase in reduction of myocardial ischaemia
in refractory unstable angina [erratum appears in Lancet 1990;335:868].
Lancet 1990;335:615-8.
204.
Holdright D, Patel D, Cunningham D, et al. Comparison of the
effect of heparin and aspirin versus aspirin alone on transient
myocardial ischemia and in-hospital prognosis in patients
with unstable angina. J Am Coll Cardiol 1994;24:39-45.
205.
Cohen M, Adams PC, Hawkins L, Bach M, Fuster V. Usefulness
of antithrombotic therapy in resting angina pectoris or non-Q-wave
myocardial infarction in preventing death and myocardial infarction
(a pilot study from the Antithrombotic Therapy in Acute Coronary
Syndromes Study Group). Am J Cardiol 1990;66:1287-92.
206.
Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin
reduces the incidence of myocardial infarction and death in
patients with unstable anginaa meta-analysis. JAMA 1996;276:811-5.
207.
Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation
of unstable angina after the discontinuation of heparin. N
Engl J Med 1992;327:141-5.
208.
Serruys PW, Herrman JP, Simon R, et al, for the Helvetica
Investigators. A comparison of hirudin with heparin in the
prevention of restenosis after coronary angioplasty. N Engl
J Med 1995;333:757-63.
209.
Global Use of Strategies to Open Occluded Coronary Arteries
(GUSTO) IIb Investigators. A comparison of recombinant hirudin
with heparin for the treatment of acute coronary syndromes.
N Engl J Med 1996;335:775-82.
210.
Granger CB, Hirsch J, Califf RM, et al. Activated partial
thromboplastin time and outcome after thrombolytic therapy
for acute myocardial infarction: results from the GUSTO-I
trial. Circulation 1996;93:870-8.
211.
Granger CB, Miller JM, Bovill EG, et al. Rebound increase
in thrombin generation and activity after cessation of intravenous
heparin in patients with acute coronary syndromes. Circulation
1995;91:1929-35.
212.
Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen
JE. Heparin and low-molecular-weight heparin: mechanisms of
action, pharmacokinetics, dosing considerations, monitoring,
efficacy, and safety. Chest 1998;114:489S-510S.
213.
Hassan WM, Flaker GC, Feutz C, Petroski GF, Smith D. Improved
anticoagulation with a weight-adjusted heparin nomogram in
patients with acute coronary syndromes: a randomized trial.
J Thromb Thrombolysis 1995;2:245-9.
214.
Becker RC, Ball SP, Eisenberg P, et al, for the Antithrombotic
Therapy Consortium Investigators. A randomized, multicenter
trial of weight-adjusted intravenous heparin dose titration
and point-of-care coagulation monitoring in hospitalized patients
with active thromboembolic disease. Am Heart J 1999;137:59-71.
215.
Hochman JS, Wali AU, Gavrila D, et al. A new regimen for heparin
use in acute coronary syndromes. Am Heart J 1999;138:313-8.
216.
Wali A, Hochman JS, Berkowitz S, et al. Failure to achieve
optimal anticoagulation with commonly used heparin regimens:
a review of GUSTO IIb (abstr). J Am Coll Cardiol 1998;31:79A.
217.
Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the
secondary prevention of coronary heart disease in men with
low levels of high-density lipoprotein cholesterol. N Engl
J Med 1999; 341:410-8.
218.
Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight
heparin with unfractionated heparin acutely and with placebo
for 6 weeks in the management of unstable coronary artery
disease. FRagmin In unstable Coronary artery disease study
(FRIC) [erratum appears in Circulation 1998;97:413]. Circulation
1997;96:61-68.
219.
FRAXIS study group. Comparison of two treatment durations
(6 days and 14 days) of a low molecular weight heparin with
a 6-day treatment of unfractionated heparin in the initial
management of unstable angina or non-Q wave myocardial infarction.
FRAX.I.S. (FRAXiparine in Ischaemic Syndrome). Eur Heart J
1999;20: 1553-62.
220.
Xiao Z, Theroux P. Platelet activation with unfractionated
heparin at therapeutic concentrations and comparisons with
a low-molecular-weight heparin and with a direct thrombin
inhibitor. Circulation 1998;97:251-6.
221.
Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia
in patients treated with low-molecular-weight heparin or unfractionated
heparin. N Engl J Med 1995;332:1330-5.
222.
Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment
of low-molecular-weight heparin (enoxaparin) versus unfractionated
heparin in acute coronary syndrome patients: results from
the ESSENCE randomized trial: Efficacy and Safety of Subcutaneous
Enoxaparin in Non-Q wave Coronary Events [unstable angina
or non-Q-wave myocardial infarction]. Circulation 1998;97:1702-7.
223.
FRagmin and Fast Revascularisation during InStability in Coronary
artery disease Investigators. Long-term low-molecular-mass
heparin in unstable coronary-artery disease: FRISC II prospective
randomised multicentre study. Lancet 1999;354:701-7.
224.
Global Use of Strategies to Open Occluded Coronary Arteries
(GUSTO) IIa Investigators. Randomized trial of intravenous
heparin versus recombinant hirudin for acute coronary syndromes.
Circulation 1994;90:1631-7.
225.
Antman EM. Hirudin in acute myocardial infarctionThrombolysis
and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B
trial. Circulation 1996;94:911-21.
226.
Antman EM. Hirudin in acute myocardial infarction: safety
report from the Thrombolysis and Thrombin Inhibition in Myocardial
Infarction (TIMI) 9A trial. Circulation 1994;90:1624-30.
227.
Organization to Assess Strategies for Ischemic Syndromes (OASIS)
Investigators. Comparison of the effects of two doses of recombinant
hirudin compared with heparin in patients with acute myocardial
ischemia without ST elevation: a pilot study. Circulation
1997;96:769-77.
228.
Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2)
Investigators. Effects of recombinant hirudin (lepirudin)
compared with heparin on death, myocardial infarction, refractory
angina, and revascularisation procedures in patients with
acute myocardial ischaemia without ST elevation: a randomised
trial. Lancet 1999;353:429-38.
229.
Williams MJ, Morison IM, Parker JH, Stewart RA. Progression
of the culprit lesion in unstable coronary artery disease
with warfarin and aspirin versus aspirin alone: preliminary
study. J Am Coll Cardiol 1997;30:364-9.
230.
Anand SS, Yusuf S, Pogue J, Weitz JI, Flather M. Long-term
oral anticoagulant therapy in patients with unstable angina
or suspected non-Q-wave myocardial infarction. Organization
to Assess Strategies for Ischemic Syndromes (OASIS) pilot
study results. Circulation 1998;98:1064-70.
231.
Anand SS, Yusuf S. Oral anticoagulant therapy in patients
with coronary artery disease: a meta-analysis. JAMA 1999;282:2058-67.
232.
Coumadin Aspirin Reinfarction Study (CARS) Investigators.
Randomised double-blind trial of fixed low-dose warfarin with
aspirin after myocardial infarction. Lancet 1997;350:389-96.
233.
Deleted during update.
234.
Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa
receptors in cardiovascular medicine. N Engl J Med 1995;332:
1553-9.
235.
Coller BS. Monitoring platelet GP IIb/IIIa [corrected] antagonist
therapy [corrected in Circulation 1998;97:5-9]. Circulation
1997;96:3828-32.
236.
Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers.
Lancet 1999;353:227-31.
237.
Coller BS. Potential non-glycoprotein IIb/IIIa effects of
abciximab. Am Heart J 1999;138:S1-5.
238.
Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab (ReoPro,
chimeric 7E3 Fab) demonstrates equivalent affinity and functional
blockade of glycoprotein IIb/IIIa and avß3 integrins. Circulation
1998;98:1085-91.
239.
Phillips DR., Scarborough RM. Clinical pharmacology of eptifibatide.
Am J Cardiol 1997;80:11B-20B.
240.
Kleiman NS. Pharmacology of the intravenous platelet receptor
glycoprotein IIb-IIIa antagonists. Cor Art Dis 1998;9:603-16.
241.
Lynch JJ Jr, Cook JJ, Sitko GR, et al. Nonpeptide glycoprotein
IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.
J Pharmacol Exp Ther 1995;272:20-32.
242.
Theroux P. Tirofiban. Drugs of Today 1999;35:59-73.
243.
Peter K, Schwarz M, Ylanne J, et al. Induction of fibrinogen
binding and platelet aggregation as a potential intrinsic
property of various glycoprotein IIb/IIIa (aIIbß3) inhibitors.
Blood 1998;92:3240-9.
244.
Use of a monoclonal antibody directed against the platelet
glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.
The EPIC Investigation. N Engl J Med 1994;330:956-61.
245.
EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor
blockade and low-dose heparin during percutaneous coronary
revascularization. N Engl J Med 1997;336:1689-96.
246.
EPISTENT Investigators. Randomised placebo-controlled and
balloon-angioplasty-controlled trial to assess safety of coronary
stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet
1998;352:87-92.
247.
Zhao XQ, Theroux P, Snapinn SM, Sax FL. Intracoronary thrombus
and platelet glycoprotein IIb/IIIa receptor blockade with
tirofiban in unstable angina or non-Q-wave myocardial infarction:
angiographic results from the PRISM-PLUS trial. Circulation
1999;100:1609-15.
248.
Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons
ML. Platelet glycoprotein IIb/IIIa receptor inhibition in
non-ST-elevation acute coronary syndromes: early benefit during
medical treatment only, with additional protection during
percutaneous coronary intervention. Circulation 1999;100:2045-8.
249.
Berkowitz SD, Sane DC, Sigmon KN, et al. Occurrence and clinical
significance of thrombocytopenia in a population undergoing
high-risk percutaneous coronary revascularization. Evaluation
of c7E3 for the Prevention of Ischemic Complications (EPIC)
Study Group. J Am Coll Cardiol 1998;32:311-9.
250.
McClure MW, Berkowitz SD, Sparapani R., et al. Clinical significance
of thrombocytopenia during a non-ST-elevation acute coronary
syndrome: the platelet glycoprotein IIb/IIIa in unstable anginareceptor
suppression using Integrilin therapy (PURSUIT) trial experience.
Circulation 1999;99:2892-900.
251.
Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto
R, for the ISIS-2 (Second International Study of Infarct Survival)
Collaborative Group. ISIS-2: 10 year survival among patients
with suspected acute myocardial infarction in randomised comparison
of intravenous streptokinase, oral aspirin, both, or neither.
BMJ 1998;316:1337-43.
252.
Franzosi MG, Santoro E, De Vita C, et al. Ten-year follow-up
of the first megatrial testing thrombolytic therapy in patients
with acute myocardial infarction: results of the Gruppo Italiano
per lo Studio della Sopravvivenza nell'Infarto-1 study. The
GISSI Investigators. Circulation 1998;98:2659-65.
253.
Miltenburg-van Zijl AJ, Simoons ML, Veerhoek RJ, Bossuyt PM.
Incidence and follow-up of Braunwald subgroups in unstable
angina pectoris. J Am Coll Cardiol 1995;25:1286-92.
254.
Nyman I, Areskog M, Areskog NH, Swahn E, Wallentin L, for
the RISC Study Group. Very early risk stratification by electrocardiogram
at rest in men with suspected unstable coronary heart disease.
J Intern Med 1993;234:293-301.
255.
Gibbons RJ, Balady GJ, Beasley JW, et al. ACC/AHA guidelines
for exercise testing: a report of the American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines (Committee on Exercise Testing). J Am Coll Cardiol
1997;30:260-311.
256.
Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA guidelines
for the clinical application of echocardiography: a report
of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (Committee on Clinical Application
of Echocardiography). Developed in collaboration with the
American Society of Echocardiography. Circulation 1997;95:1686-744.
257.
Ritchie JL, Bateman TM, Bonow RO, et al. Guidelines for the
clinical use of cardiac radionuclide imaging: report of the
American College of Cardiology/American Heart Association
Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular
Procedures (Committee on Radionuclide Imaging). Developed
in collaboration with the American Society of Nuclear Cardiology.
J Am Coll Cardiol 1995;25:521-47.
258.
Mark DB, Shaw L, Harrell FEJ, et al. Prognostic value of a
treadmill exercise score in outpatients with suspected coronary
artery disease. N Engl J Med 1991;325:849-53.
259.
Nyman I, Larsson H, Areskog M, Areskog NH, Wallentin L. The
predictive value of silent ischemia at an exercise test before
discharge after an episode of unstable coronary artery disease.
RISC Study Group. Am Heart J 1992;123:324-31.
260.
Starling MR, Crawford MH, Kennedy GT, O'Rourke RA. Treadmill
exercise tests predischarge and six weeks post-myocardial
infarction to detect abnormalities of known prognostic value.
Ann Intern Med 1981;94:721-7.
261.
Marwick TH, Anderson T, Williams MJ, et al. Exercise echocardiography
is an accurate and cost-efficient technique for detection
of coronary artery disease in women. J Am Coll Cardiol 1995;26:335-41.
262.
Larsson H, Areskog M, Areskog NH, et al. Should the exercise
test (ET) be performed at discharge or one month later after
an episode of unstable angina or non-Q-wave myocardial infarction?
Int J Card Imaging 1991;7:7-14.
263.
Russo CA, Dai H, Chow BK, et al. Analysis of death during
the first twelve months among non-Q wave MI patients randomized
to an "invasive" vs. "conservative" management strategy: results
from the VANQWISH trial (abstr). Circulation (Suppl I)1998;
98:I492.
264.
Scanlon PJ, Faxon DP, Audet A, et al. ACC/AHA guidelines for
coronary angiographya report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines (Committee
on Coronary Angiography). J Am Coll Cardiol 1999;33:1756-824.
265.
McCullough PA, O'Neill WW, Graham M, et al. A prospective
randomized trial of triage angiography in acute coronary syndromes
ineligible for thrombolytic therapy: results of the Medicine
versus Angiography in Thrombolytic Exclusion (MATE) trial.
J Am Coll Cardiol 1998;32:596-605.
266.
Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients
with acute non-Q-wave myocardial infarction randomly assigned
to an invasive as compared with a conservative management
strategy. Veterans Affairs Non-Q-Wave Infarction Strategies
in Hospital (VANQWISH) Trial Investigators [erratum appears
in N Engl J Med 1998;339:1091]. N Engl J Med 1998;338:1785-92.
267.
RITA-2 Trial Participants. Coronary angioplasty versus medical
therapy for anginathe second Randomised Intervention Treatment
of Angina (RITA-2) trial. Lancet 1997;350:461-8.
268.
Peterson ED, Shaw LJ, Califf RM. Risk stratification after
myocardial infarction. Ann Intern Med 1997;126:561-82.
269.
Luchi RJ, Scott SM, Deupree RH. Comparison of medical and
surgical treatment for unstable angina pectoris: results of
a Veterans Administration Cooperative Study. N Engl J Med
1987;316:977-84
270.
Takaro T, Hultgren H, Lipton MJ, et al. The VA Cooperative
Randomized Study of Surgery for Coronary Arterial Occlusive
Disease, II: subgroup with significant left main lesions.
Circulation 1976;54(Suppl III):III-107-17.
271.
Kereiakes DJ, McDonald M, Broderick TM, et al. Abciximab provides
cost efficient, safely expedited care for unstable angina
(abstr). Cathet Cardiovasc Diagn 1999;47:137.
272.
Laskey MA, Deutsch E, Barnathan E, Laskey WK. Influence of
heparin therapy on percutaneous transluminal coronary angioplasty
outcome in unstable angina pectoris. Am J Cardiol 1990; 65:1425-9.
273.
Deleted during update.
274.
Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA guidelines
for coronary artery bypass graft surgery: a report of the
American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (Committee on Coronary Artery
Bypass Graft Surgery). J Am Coll Cardiol 1999;34:1262-347.
275.
Madsen JK, Grande P, Saunamaki K, et al. Danish multicenter
randomized study of invasive versus conservative treatment
in patients with inducible ischemia after thrombolysis in
acute myocardial infarction (DANAMI). DANish trial in Acute
Myocardial Infarction. Circulation 1997;96:748-55.
276.
Pepine CJ, Geller NL, Knatterud GL, et al. The Asymptomatic
Cardiac Ischemia Pilot (ACIP) study: design of a randomized
clinical trial, baseline data and implications for a long-term
outcome trial [erratum appears in J Am Coll Cardiol 1995;26:842].
J Am Coll Cardiol 1994;24:1-10.
277.
Knatterud GL, Bourassa MG, Pepine CJ, et al. Effects of treatment
strategies to suppress ischemia in patients with coronary
artery disease: 12-week results of the Asymptomatic Cardiac
Ischemia Pilot (ACIP) study [erratum appears in J Am Coll
Cardiol 1995;26:842]. J Am Coll Cardiol 1994;24:11-20.
278.
FRagmin and Fast Revascularisation during InStability in Coronary
artery disease Investigators. Invasive compared with non-invasive
treatment in unstable coronary-artery disease: FRISC II prospective
randomised multicentre study. Lancet 1999;354:708-15.
278a.
Wallentin L, Lagerqvist B, Husted S, et al. Outcome at one
year after an invasive compared with a non-invasive strategy
in unstable coronary artery disease: the FRISC II invasive
randomized trial. Lancet 2000;356:9-16.
279.
Yusuf S, Flather M, Pogue J, et al. Variations between countries
in invasive cardiac procedures and outcomes in patients with
suspected unstable angina or myocardial infarction without
initial ST elevation. OASIS (Organisation to Assess Strategies
for Ischaemic Syndromes) Registry Investigators. Lancet 1998;352:
507-14.
280.
Ghazzal P, Chalasani Y, Weintraub WS. Long term outcome of
patients with non-Q wave myocardial infarction with or without
revascularization (abstr). J Am Coll Cardiol 1998;31:14A.
281.
Deleted during update.
282.
Stone PH, Thompson B, Zaret BL, et al. Factors associated
with failure of medical therapy in patients with unstable
angina and non-Q wave myocardial infarction: a TIMI IIIB database
study. Eur Heart J 1999;20:1084-93.
283.
Bugiardini R, Pozzati A, Borghi A, et al. Angiographic morphology
in unstable angina and its relation to transient myocardial
ischemia and hospital outcome. Am J Cardiol 1991;67:460-4.
284.
Boden WE, Kerensky RA, Bertolet BD, et al. Coronary angiographic
findings after non-Q wave myocardial infarction: an analysis
from the VANQWISH trial (abstr). Eur Heart J 1997; 18:123.
285.
Diver DJ, Bier JD, Ferreira PE, et al. Clinical and arteriographic
characterization of patients with unstable angina without
critical coronary arterial narrowing (from the TIMI-IIIA trial).
Am J Cardiol 1994;74:531-7.
286.
Albertsson P, Emanuelsson H, Karlsson T, et al. Morbidity
and use of medical resources in patients with chest pain and
normal or near-normal coronary arteries. Am J Cardiol 1997;79:299-304.
287.
Potts SG, Bass CM. Psychosocial outcome and use of medical
resources in patients with chest pain and normal or near-normal
coronary arteries: a long-term follow-up study. Q J Med 1993;86:
583-93.
288.
Jones RH, Kesler K, Phillips HR, et al. Long-term survival
benefits of coronary artery bypass grafting and percutaneous
transluminal angioplasty in patients with coronary artery
disease. J Thorac Cardiovasc Surg 1996;111:1013-25.
289.
Hannan EL, Racz MJ, McCallister BD, et al. A comparison of
three-year survival after coronary artery bypass graft surgery
and percutaneous transluminal coronary angioplasty. J Am Coll
Cardiol 1999;33:63-72.
290.
Rahimtoola SH, Nunley D, Grunkemeier G, Tepley J, Lambert
L, Starr A. Ten-year survival after coronary bypass surgery
for unstable angina. N Engl J Med 1983;308:676-81.
291.
Levin TN, Holloway S, Feldman T. Acute and late clinical outcome
after rotational atherectomy for complex coronary disease.
Cathet Cardiovasc Diagn 1998;45:122-30.
292.
Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after
revasculari | 
